Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

September 04, 2015 3:12 PM ET


Company Overview of MSD K.K.

Company Overview

MSD K.K. develops, manufactures, and sells pharmaceutical products in Japan. It offers prescription drugs and vaccines in various therapeutic areas, including cardiovascular, respiratory, hepatitis, bone and skin diseases, central nervous system, anesthesiology, cancer, women’s health, and ophthalmic diseases. MSD K.K. was formerly known as Banyu Pharmaceutical Co., Ltd. and changed its name to MSD K.K. in October 2010. The company was founded in 1915 and is headquartered in Tokyo, Japan. MSD K.K. operates as a subsidiary of Merck & Co. Inc.

Kitanomaru Square

1-13-12, Kudan-kita


Tokyo,  102-8667


Founded in 1915


81 3 6272 1000


81 3 6238 9057

Key Executives for MSD K.K.

Managing Director
President and Representative Director
Senior Vice President, Head of Administration Division and Executive Director
Senior Vice President and Head of Marketing & Sales Division
Deputy Head of Production Division
Compensation as of Fiscal Year 2015.

MSD K.K. Key Developments

Astellas Pharma, Inc. and MSD K.K. Announce Availability of Diabetes Drug in Japan

Astellas Pharma, Inc. and MSD K.K. have announced the availability of Suglat tablets 25mg and 50mg for the indication of type 2 diabetes in Japan. Suglat Tablets is a selective SGLT2 (Sodium-Glucose Co-Transporter 2) inhibitor discovered through a research collaboration and is being jointly developed by Astellas and Kotobuki Pharmaceutical Co. Ltd. SGLTs are membrane proteins that exist on the cell surface and transfer glucose into cells. SGLT2 is one subtype of SGLTs and plays a key role in the reuptake of glucose in the proximal tubule of the kidneys. Suglat Tablets reduces blood glucose levels by inhibiting the reuptake of glucose by selectively inhibiting SGLT2. Suglat Tablets is the first SGLT2 inhibitor approved as a treatment for type 2 diabetes in Japan. Astellas will manufacture and sell Suglat Tablets and co-promote it with Kotobuki and MSD.

MSD K.K. Presents at BioJapan 2013 World Business Forum, Oct-09-2013

MSD K.K. Presents at BioJapan 2013 World Business Forum, Oct-09-2013 . Venue: Pacifico Yokohama, Yokohama, Japan.

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MSD K.K., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at